The short version of GLP-1 receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-21 and is reviewed periodically as new material appears.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | GLP-1 receptor agonist peptide | Mimics endogenous incretin signaling |
| Molecular mass | Approximately 4114 Da | Modified 31-amino-acid backbone |
| Appearance | White to off-white powder | Typical of lyophilized peptide material |
| Solubility | Soluble in water | Behavior depends on salt form and buffer |
| Elimination half-life | About one week | Supported by albumin binding and protease resistance |
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Historically to protect people's privacy and correspondence, the post banned tampering with letters, and excluded post offices from responsibility for letters even if the contents were for something illegal. As the internet developed, the original Information Society Directive 1998 aimed for something similar, so that internet server providers or email hosts, for instance, protected privacy. After this the Electronic Commerce Directive 2000 also sought to ensure free movement for an "information society service", requiring member states to not restrict them unless it was to fulfill a public policy, prevent crime, fight incitement to hatred, protect individual dignity, protect health, or protect consumers or investors. Articles 12 to 14 further said that an ISS operating as a "mere conduit" for information, doing "caching" or "hosting" is 'not liable for information stored' if the 'provider does not have actual knowledge of illegal activity' and 'is not aware of facts or circumstances from which the illegal activity or information is apparent', but must act quickly to remove or disable access 'upon obtaining knowledge or awareness'. Article 15 states that member states should 'not impose a general obligation on providers... to monitor the information which they transmit or store' nor 'seek facts' on illegality. However the meaning of who was an "ISS" was not clearly defined in law, and has become a problem with social media that was not meant to be protected like private communication.
=== Environment === Deforestation in the Brazilian Amazon rainforest fell 61% in January 2023 from a year earlier following a series of anti-logging and anti-mining operations launched by government agencies under Lula, according to satellite data. In June 2023, the Environment Ministry announced a plan to curb deforestation in Brazil's Legal Amazon, and immediately embargoed all activities being developed inside conservation parks in the region. Additionally, the government announced the creation of 3 million hectares (7,413,161.44 acres) in protected areas until 2027/ the creation of tracking system using geopositioning for Amazon agricultural products and ecolabels were announced as well. In July 2023, deforestation in the Brazilian Amazon was reported to have fallen 34% over the previous six months while deforestation in the Brazilian Atlantic forest dropped 42% from January to May 2023 comparatively to the same period of time in 2022. In November 2023, Brazil's National Institute for Space Research (INPE) reported that the Amazon deforestation rate fell 22% between August 2022 and July 2023, compared to its previous 2021–2022 report (during Jair Bolsonaro's presidency). Considering only the period of the Lula government, the drop is accentuated to 49.7% compared to the same period of the previous year. Deforestation in protected areas fell the most, being the lowest in 9 years. In total, Imazon highlighted that 2023 had the lowest deforestation rate since 2017.
== History == Mesocarb was first described in the scientific literature by 1971. It is said to have been used as a pharmaceutical drug from 1971 until 2008. It was said to have been discontinued by its manufacturer in 2008 for business reasons unrelated to the drug itself.
Sources: en.wikipedia.org
Abnormal basal metabolic rate refers to a high or low basal metabolic rate (BMR). It has numerous causes, both physiological (part of the body's normal function) and pathological (associated with disease). An abnormal basal metabolic rate is not necessarily indicative of disease; a number of physiological factors can alter the BMR by influencing cellular metabolic activity. For instance, males are more likely than females to have a high BMR, and in women, the BMR may rise to abnormal levels during pregnancy or lactation. An individual's BMR varies greatly with age: infants and children typically have a high BMR, required for growth, while the elderly have a low BMR. Tall, thin people have a higher BMR than their shorter counterparts, even with the same weight, due to the greater surface area of their skin. The metabolic rate also decreases during sleep and increases in exercise, and individuals who exercise regularly have a higher BMR than those who are sedentary. Environmental temperature also has an effect: the BMR is increased in both heat and cold.
=== Naming === Using Mendeleev's nomenclature for unnamed and undiscovered elements, roentgenium should be known as eka-gold. In 1979, IUPAC published recommendations according to which the element was to be called unununium (with the corresponding symbol of Uuu), a systematic element name as a placeholder, until the element was discovered (and the discovery then confirmed) and a permanent name was decided on. Although widely used in the chemical community on all levels, from chemistry classrooms to advanced textbooks, the recommendations were mostly ignored among scientists in the field, who called it element 111, with the symbol of E111, (111) or even simply 111. The name roentgenium (Rg) was suggested by the GSI team in 2004, to honor the German physicist Wilhelm Conrad Röntgen, the discoverer of X-rays. This name was accepted by IUPAC on November 1, 2004.
===== Sweden ===== Cannabidiol is classified as a medical product in Sweden. However, in July 2019, Supreme Court of Sweden ruled that CBD oil with any concentration of THC falls under the narcotic control laws.
=== U.S. response on humanitarian aid === In May 2026, U.S. Secretary of State Marco Rubio said the United States had offered $100 million in humanitarian aid to Cuba, including food and medical supplies. He criticized the Cuban government, saying it was preventing humanitarian aid from reaching the population. The statement was made in the context of long-standing U.S. sanctions and trade restrictions on Cuba, which have restricted economic and humanitarian flows to the country. Rubio also described the situation in Cuba as "unacceptable" and called for major changes in the country's governance.
Sources: en.wikipedia.org
=== Degrowth === Effective accelerationism stands in stark contrast with the degrowth movement, sometimes described by it as "decelerationism" or "decels". The degrowth movement advocates for reducing economic activity and consumption to address ecological and social issues. Effective accelerationism on the contrary embraces technological progress, energy consumption and the dynamics of capitalism, rather than advocating for a reduction in economic activity.
In summary, about 193 commuter trains turn around in Penn Station during the combined Peak service periods, and 111 commuter trains run-through to West Side or Sunnyside Yards. As both yards are at their practical capacity, any major increase in revenue-to-storage through-running would require major expansion of yard capacity.
Retinol is available as a generic medication and is also used in over-the-counter cosmetic products. In 2021, vitamin A was the 298th most commonly prescribed medication in the United States, with more than 500,000 prescriptions.
The survival of Franz Joseph was also commemorated in Prague by erecting a new statue of St. Francis of Assisi, the patron saint of the emperor, on Charles Bridge. It was donated by Count Franz Anton von Kolowrat-Liebsteinsky, the first minister-president of the Austrian Empire.
=== Public awareness === Public awareness of the disease, which is spread through the exchange of bodily fluids, is not as high as it is for HIV and AIDS. In some rural areas, doctors have reused syringes and unknowingly spread the disease, particularly among children.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.
Yes. Stimulation of insulin secretion is glucose-dependent, meaning the effect is larger when blood glucose is high and minimal when it is normal. This property separates GLP-1 receptor agonists from agents that drive insulin release regardless of glucose level.
Receptor expression in hypothalamic and brainstem regions is well documented, and reduced energy intake is consistently observed. The relative contribution of central versus peripheral signaling to total weight change is still an open question addressed by ongoing research.
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.